| Literature DB >> 31669058 |
Thomas A Pollak1, Belinda R Lennox2, Sabine Müller3, Michael E Benros4, Harald Prüss5, Ludger Tebartz van Elst6, Hans Klein7, Johann Steiner8, Thomas Frodl8, Bernhard Bogerts8, Li Tian9, Laurent Groc10, Alkomiet Hasan11, Bernhard T Baune12, Dominique Endres6, Ebrahim Haroon13, Robert Yolken14, Francesco Benedetti15, Angelos Halaris16, Jeffrey H Meyer17, Hans Stassen18, Marion Leboyer19, Dietmar Fuchs20, Markus Otto21, David A Brown22, Angela Vincent23, Souhel Najjar24, Karl Bechter25.
Abstract
There is increasing recognition in the neurological and psychiatric literature of patients with so-called isolated psychotic presentations (ie, with no, or minimal, neurological features) who have tested positive for neuronal autoantibodies (principally N-methyl-D-aspartate receptor antibodies) and who have responded to immunotherapies. Although these individuals are sometimes described as having atypical, mild, or attenuated forms of autoimmune encephalitis, some authors feel that that these cases are sufficiently different from typical autoimmune encephalitis to establish a new category of so-called autoimmune psychosis. We briefly review the background, discuss the existing evidence for a form of autoimmune psychosis, and propose a novel, conservative approach to the recognition of possible, probable, and definite autoimmune psychoses for use in psychiatric practice. We also outline the investigations required and the appropriate therapeutic approaches, both psychiatric and immunological, for probable and definite cases of autoimmune psychoses, and discuss the ethical issues posed by this challenging diagnostic category.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31669058 DOI: 10.1016/S2215-0366(19)30290-1
Source DB: PubMed Journal: Lancet Psychiatry ISSN: 2215-0366 Impact factor: 27.083